Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Cancer, Ltd. presented updated Phase 1 trial data showing six of ten heavily pre-treated cancer patients remain alive 22-40 months after a single UNO (ultra-high concentration nitric oxide) injection. Two triple negative breast cancer patients showed no evidence of disease. The company also received a U.S. patent allowance for its proprietary gas delivery technology. Safety profile was generally favorable with mostly Grade 1-2 adverse events.

04/20/2026, 8:00 AM • GlobeNewswire

Beyond Air to Participate in the 38th Annual Roth Conference in March

Beyond Air, Inc. (NASDAQ: XAIR) announced that Chairman & CEO Steve Lisi will participate in the 38th Annual Roth Conference on March 23, 2026, in Laguna Niguel, CA. The company will present via fireside chat and offer one-on-one meetings with investors. Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide therapies for respiratory illnesses, neurological disorders, and solid tumors.

03/11/2026, 7:00 AM • GlobeNewswire

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

Beyond Air commented on the publication of an independent peer-reviewed article in Intensive Care Medicine Experimental that highlights the therapeutic potential of high-dose inhaled nitric oxide (iNO) for treating respiratory infections. The article synthesized data from 27 studies showing high-dose iNO's multimodal antimicrobial activity and potential applications in hospital-acquired pneumonia, COVID-19, bronchiolitis, and nontuberculous mycobacteria. Beyond Air's CEO stated the publication validates the company's clinical programs and could accelerate development of high-dose iNO as a transformative treatment.

02/20/2026, 8:00 AM • GlobeNewswire

Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments

Beyond Air Inc. (NASDAQ:XAIR) has agreed to sell 85% of its subsidiary NeuroNOS Ltd. to XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) in exchange for 19.9% equity stake in XTL, $1 million cash, and up to $32.5 million in milestone-based payments. NeuroNOS, which focuses on autism therapeutics and holds FDA Orphan Drug Designations, will become XTL's flagship platform. Beyond Air shares surged 163.70% on the announcement.

01/13/2026, 1:40 PM • Benzinga

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

XTL Biopharmaceuticals announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc., positioning itself as a major player in autism therapeutics. The acquisition includes two Nobel Laureates in Chemistry and autism researcher Prof. Haitham Amal. NeuroNOS has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma. XTL will pay 19.9% of its share capital, $1 million cash, and up to $32.5 million in milestone payments.

01/13/2026, 9:28 AM • Benzinga

Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds

Beyond Air will exercise existing warrants to purchase 1,439,126 shares at $2.21 per share, generating approximately $3.25 million in gross proceeds. The company will simultaneously issue new unregistered warrants and plans to use the funds for clinical programs and operating expenses.

09/08/2025, 3:55 PM • GlobeNewswire

Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

Beyond Air has signed new distribution agreements in Japan, South Korea, Costa Rica, Guatemala, Panama, and El Salvador, expanding its international LungFit PH network to 34 countries representing 2.7 billion people.

08/20/2025, 8:00 AM • GlobeNewswire

Beyond Air Sales Jump 158 Percent

Beyond Air reported Q1 fiscal 2026 results with 157% revenue growth to $1.8 million, but missed analyst estimates. The company expanded international sales, reduced expenses, and made regulatory progress in nitric oxide therapies.

08/18/2025, 5:24 PM • The Motley Fool

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

Beyond Air, a medical device and biopharmaceutical company, will report its Q1 2025 financial results on August 12, 2025, and host a conference call to discuss its developments in nitric oxide-based medical treatments.

07/25/2025, 8:00 AM • GlobeNewswire